A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients

Trial Profile

A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs CLR 325 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 18 Aug 2017 Planned number of patients changed from 16 to 40.
    • 09 Apr 2017 Planned End Date changed from 28 Aug 2017 to 24 Sep 2018.
    • 09 Apr 2017 Planned primary completion date changed from 28 Aug 2017 to 24 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top